These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25780477)

  • 21. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study.
    Yoshida N; Babazono T; Hanai K; Uchigata Y
    Int Urol Nephrol; 2016 Aug; 48(8):1349-1355. PubMed ID: 27193434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.
    Ishikawa M; Takai M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2015 Aug; 7(8):607-12. PubMed ID: 26124906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
    Underland LJ; Ilkowitz JT; Katikaneni R; Dowd A; Heptulla RA
    J Diabetes Sci Technol; 2017 May; 11(3):602-610. PubMed ID: 28349708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
    Pasquel FJ; Gianchandani R; Rubin DJ; Dungan KM; Anzola I; Gomez PC; Peng L; Hodish I; Bodnar T; Wesorick D; Balakrishnan V; Osei K; Umpierrez GE
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):125-133. PubMed ID: 27964837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance.
    Horie A; Tokuyama Y; Ishizuka T; Suzuki Y; Marumo K; Oshikiri K; Ide K; Sunaga M; Kanatsuka A
    Horm Metab Res; 2014 Oct; 46(11):814-8. PubMed ID: 24977657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
    Mari A; Sallas WM; He YL; Watson C; Ligueros-Saylan M; Dunning BE; Deacon CF; Holst JJ; Foley JE
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4888-94. PubMed ID: 15886245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
    Shimizu S; Hosooka T; Matsuda T; Asahara S; Koyanagi-Kimura M; Kanno A; Bartolome A; Etoh H; Fuchita M; Teruyama K; Takahashi H; Inoue H; Mieda Y; Hashimoto N; Seino S; Kido Y
    J Mol Endocrinol; 2012 Oct; 49(2):125-35. PubMed ID: 22822047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.
    Yuasa S; Sato K; Takai M; Ishikawa M; Umezawa S; Kubota A; Maeda H; Kanamori A; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Jun; 8(6):461-71. PubMed ID: 27222674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.
    Rizos EC; Ntzani EE; Papanas N; Tsimihodimos V; Mitrogianni Z; Maltezos E; Elisaf MS
    Curr Vasc Pharmacol; 2013 Nov; 11(6):992-1000. PubMed ID: 22724475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
    Hoste J; Daci E; Mathieu C
    Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
    Kostev K; Schokker E; Jacob L
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis.
    Mera J; Okada E; Okuda M; Ota T; Sibata S; Uchida S
    J Diabetes Metab Disord; 2015; 14():83. PubMed ID: 26550558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of vildagliptin in korean patients with type 2 diabetes.
    Moon JS; Won KC
    Diabetes Metab J; 2013 Feb; 37(1):36-9. PubMed ID: 23441298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.